Entero Therapeutics Inc..
ENTO.US | Research and experimental development on natural sciences and engineering
Entero Therapeutics Inc. is a biotechnology company focused on the research and development of novel therapies. While specific details about their therapeutic areas and product pipeline are not available, the company's activities likely involve preclinical and clinical research, drug discovery, and ...Show More
Better Health for All
10
Entero Therapeutics Inc. is a biotechnology company focused on the research and development of novel therapies, with its entire business devoted to health improvement. Its primary product, adrulipase, is being developed as a treatment for exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) and chronic pancreatitis (CP) patients, aiming to improve fat absorption and reduce digestive distress.
1
This product is currently in Phase 2 clinical trials.
2
The enhanced adrulipase formulation was found to be safe and well-tolerated in the Phase 2 trial.
3
The company is investing in the research and development of this new treatment, which is currently in Phase 2, with a planned FDA End-of-Phase 2 meeting in the fourth quarter of 2023.
4
Fair Money & Economic Opportunity
0
No evidence available to assess Entero Therapeutics Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
10
The company has an average employee recommendation score of 3.86 out of 5 from Glassdoor reviews, which translates to approximately 77.2%.
1
This indicates a healthy workplace culture. No specific, concrete data points were found for living wage coverage, CEO median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, voluntary turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.
2
While all non-essential employees were laid off, and a CEO consulting fee of $400/hour was noted, these facts do not map to the specific quantitative thresholds of the other KPIs.
3
Fair Trade & Ethical Sourcing
0
No evidence available to assess Entero Therapeutics Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess Entero Therapeutics Inc. on Honest & Fair Business.
Kind to Animals
0
Entero Therapeutics Inc. used a total of 26 dogs in a study published in May 2010.
1
This included 6 dogs for a simvastatin experiment and an additional 20 dogs for initial safety and tolerability investigations of the Entero-Test device.
2
The company also developed the Entero-Test as a novel, non-invasive method for collecting bile samples from dogs, which potentially reduces the need for more invasive surgical procedures.
3
No War, No Weapons
0
No evidence available to assess Entero Therapeutics Inc. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess Entero Therapeutics Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
The provided articles do not contain any specific, factual data points related to Entero Therapeutics Inc.'s respect for cultures and communities. Information regarding formal partnerships, community investment, cultural incidents, impact assessments, local employment, grievance mechanisms, or any other relevant metrics for this value is absent. explicitly notes a "Lack of data on community engagement, cultural impact, and social license to operate."
1
Safe & Smart Tech
-10
Entero Therapeutics Inc. has reported no material cybersecurity threats or incidents, nor any incidents of unauthorized data use.
1
The company states that encryption is used for sensitive data transmission, such as credit card information.
2
Users can request access, correction, or deletion of their data and opt-out of future communications.
3
The company collects data only as needed and does not sell or rent it, but specific retention policies are not provided.
4
The company uses NIST CSF 2.0 for guidance, not compliance, which indicates a basic approach to regulatory compliance.
5
Zero Waste & Sustainable Products
0
No specific, concrete data points were found in the provided articles regarding ENTO.US's performance on any of the 'Zero Waste & Sustainable Products' KPIs. The articles discuss general industry trends, challenges, and solutions related to sustainable packaging and waste reduction in the life sciences and pharmaceutical sectors, but do not provide any direct evidence or metrics attributable to ENTO.US.